Please use this identifier to cite or link to this item:
Title: AKT inhibitor ARQ 092 and sorafenib additively inhibit progression of hepatocellular carcinoma and improve immune system in cirrhotic rat model
Authors: Jilkova, Z. M.
Zeybek Kuyucu, Ayça
Kurma, K.
Pour, S. T. A.
Roth, G. S.
Abbadessa, G.
Decaens, T.
Publisher: Elsevier
Abstract: Background and Aims: Hepatocellular carcinoma (HCC) is often diagnosed at advanced stages with limited number of therapeutic options. Longer exposure to classical treatment of advanced HCC, sorafenib, often over-activates AKT pathway, leading to HCC resistance. Moreover, AKT pathway itself is activated in almost half of HCC cases. Therefore, we investigated the efficacy of combination of Sorafenib with allosteric Akt inhibitor ARQ 092 in a DEN-induced cirrhotic rat model with HCC.
Description: International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver -- APR 19-23, 2017 -- Amsterdam, NETHERLANDS
ISSN: 0168-8278
Appears in Collections:Bioengineering / Biyomühendislik
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
1-s2.0-S0168827817317361-main.pdf61.74 kBAdobe PDFView/Open
Show full item record

CORE Recommender

Page view(s)

checked on Apr 8, 2024


checked on Apr 8, 2024

Google ScholarTM



Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.